Elanco Animal Health (ELAN) BofA Securities Animal Health Summit summary

Strategic and financial highlights

• Achieved strong performance in adjusted EBITDA, revenue, and EPS, surpassing expectations for the year, with all business quadrants showing growth driven by innovation and international expansion.

• Guidance for 2026 aligns with prior targets: mid-single-digit top-line growth, high single-digit EBITDA growth, and low double-digit EPS growth, with plans to delever to low threes by year-end.

• Raised innovation revenue target from $1.1B to $1.15B, reflecting momentum in new product launches and pipeline strength.

• Continued focus on operational excellence and funding R&D through the Ascend initiative to support both short- and long-term growth.

• Pricing expected to accelerate in 2026, with the highest U.S. vet clinic price increases in five years, driven by portfolio upgrades and new product launches.

Innovation and product portfolio

• Zenrelia demonstrated strong international uptake, with significant market share gains in Brazil, Japan, and Europe, and growing U.S. clinic adoption following a label update.

• Ongoing constructive dialogue with the FDA regarding further label improvements for Zenrelia, with potential catalysts expected mid-year, though current guidance assumes no label change.

• Befreba set for a phased Q2 launch, expected to further differentiate the portfolio and drive growth, with manufacturing on track and positive feedback from veterinarians.

• Quattro achieved blockbuster status, outpacing expectations with strong differentiation in efficacy, palatability, and market share gains, especially in the Para segment.

• The innovation basket, including Zenrelia, Befreba, and Quattro, is positioned as best-in-class, with a portfolio approach and omnichannel strategy supporting continued share gains.

Competitive landscape and market dynamics

• Competitive entries, such as Merck’s Nuvimelvi, were anticipated and factored into guidance; Zenrelia has outperformed competitors in Europe and is leveraging head-to-head data.

• The market is expected to grow by $20B over the next decade, with the company focused on value and efficacy rather than price competition.

• Distribution relationships remain strong, with a buy-sell model across the full portfolio and constructive partnerships with major distributors, providing a tailwind for product launches.

• The company’s commercial engine, including the largest sales force in pet health, is driving adoption and leveraging omnichannel and subscription models for compliance and growth.